ECM
BMY icon

ExodusPoint Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

ExodusPoint Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-40,000
Closed -$1.81M – 1345
2019
Q2 		$1.81M Buy
+40,000
New +$1.86M 0.07% 168

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ExodusPoint Capital Management's BMY Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 61% in Q1 2026, selling an estimated $9.91M and leaving 110,185 shares worth $6.68M. The position accounts for 0.05% of the portfolio, ranked #349.

ExodusPoint Capital Management first reported a position in BMY in Q4 2018 and has held it in 19 quarters since. The position peaked at $41.9M in Q1 2023. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • ExodusPoint Capital Management held 110,185 shares of Bristol-Myers Squibb worth $6.68M as of Q1 2026.
  • ExodusPoint Capital Management sold 170,049 Bristol-Myers Squibb shares in Q1 2026, an estimated $9.91M.
  • Bristol-Myers Squibb made up 0.05% of ExodusPoint Capital Management's portfolio in Q1 2026, its #349 holding.
  • ExodusPoint Capital Management first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 19 quarters since.
  • ExodusPoint Capital Management's Bristol-Myers Squibb position peaked at $41.9M in Q1 2023.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.